Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential

Status Recruiting

Clinical Trial Summary

This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.

Clinical Trial Description

This study is intended to lead to the development and demonstration of a breathalyzer instrument capable of detecting and quantitatively measuring drugs (i.e. cannabinoids and opioids) in exhaled breath (EB). Prior work on the detection of these drugs in EB by means of liquid chromatography and mass spectrometry (LC/MS) demonstrated that these compounds can be quantitatively detected, but LC/MS is slow, expensive and requires highly skilled personnel to implement. What is needed is a simple and inexpensive method for rapidly measuring the amount of drugs in EB. If such a method becomes available it can be used by law enforcement and in doctors' offices, hospital emergency rooms, ambulances and other government agencies, military bases and companies seeking to screen employees for drug abuse. Vox Biomedical proposes to develop a method for quantitatively detecting the presence of drugs in EB by means of Differential Mobility Spectrometry (DMS) developed at Draper Laboratories. DMS is a robust, datarich, ultra-trace, chemical detection technology that has been proven for numerous applications including air quality cabin monitoring on the International Space Station (ISS), chemical warfare agent detection, explosives detection, and drinking water analysis. Recently Draper has applied this device to breath analysis for the detection of lung diseases. A clinical study is currently underway and initial results are promising. This project involves transferring this technology developed by Draper for lung infection detection to the detection of psychoactive drugs in exhaled breath. Phase I of the proposed program will investigate the DMS signatures of cannabinoids in the laboratory and defining the device's limits of detection. A small pilot study will also be performed to demonstrate feasibility for using breath analysis as a proxy for the concentration of cannabinoids in the blood. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05384470
Study type	Interventional
Source	Mclean Hospital
Contact	Scott E. Lukas, Ph.D.
Phone	617-855-2767
Email	slukas@mclean.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	July 1, 2021
Completion date	October 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01539525` - Screening to Augment Referral to Treatment- Project START	Phase 2
Completed	`NCT00158249` - Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals	Phase 2
Completed	`NCT00842985` - Dronabinol Interactions in Humans	N/A
Completed	`NCT00484302` - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis	N/A
Completed	`NCT00227864` - A Brief Marijuana Intervention for Adolescent Women - 1	Phase 3
Completed	`NCT00227903` - Therapeutic Substance Abuse Treatment in Pregnancy - 1	Phase 2
Completed	`NCT00218478` - Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1	Phase 1
Completed	`NCT00249509` - Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals	Phase 2
Completed	`NCT03717272` - Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects	Phase 2
Completed	`NCT00142961` - Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder	Phase 2
Terminated	`NCT02102230` - CBT-I for Cannabis Use	N/A
Completed	`NCT00580671` - Treatment for Adolescent Marijuana Abuse	N/A
Completed	`NCT00360269` - Atomoxetine Treatment for ADHD and Marijuana Dependence	Phase 2
Completed	`NCT00227916` - Motivational Interviews for Incarcerated Teens - 1	N/A
Completed	`NCT03154567` - Effects of Stress and Drug-cue Exposure (SCM)	Phase 1
Active, not recruiting	`NCT05322941` - Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)	Phase 2
Completed	`NCT02797990` - Conflict Between Maternal Autonomy and Child Health in Substance-use	N/A
Completed	`NCT01762696` - A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth	N/A
Completed	`NCT03154580` - Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users	Phase 1
Completed	`NCT00217971` - Dronabinol Treatment for Marijuana Addiction	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms